Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
about
Enhancing Cancer Immunotherapy Via Activation of Innate ImmunityNK cell-based immunotherapy for malignant diseases.Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis.NK cell-based immunotherapies in Pediatric Oncology.Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.(19)F-MRI for monitoring human NK cells in vivoIn Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Immunocytokines for cancer treatment: past, present and future.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Glycans as targets for therapeutic antitumor antibodies.Immunocytokines: a review of molecules in clinical development for cancer therapy.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Delivering safer immunotherapies for cancer.High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles.Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.Immunocytokines
P2860
Q26796313-0C94B2FA-D0DB-4A44-8780-491020D7CA52Q33827433-E081A8D0-E6FB-4FC1-83A0-5178F1AFA2E2Q34129154-B2DBDAC2-4961-416A-9860-239182BF4761Q35031732-45B5C7AD-1344-4D61-AEDF-D8425589C931Q35077925-74E00F95-5B68-4148-9983-33CC891AA11FQ35600975-86FE90AA-E13B-423D-A0D9-FB7B5F2331ABQ35963440-DFEB687B-B9D7-44BC-A0D6-B13DB1046547Q36179663-3A8A94C0-E699-4FCB-869F-B61DF42B4631Q37012655-65BB5F1B-3D0F-47F3-936C-7403D47C4235Q37059790-F9BD2D6F-107C-42D5-A51A-9EDAC516CA39Q37560208-4EF85350-25BB-4CFB-9527-30393A3C53F8Q37637949-FE61C4D8-AA60-4554-A23E-6EBB621C03D3Q38034815-9EA86DB7-AD57-4A62-8700-D08526D2C7F9Q38132742-D70055C5-5B64-450B-8E3D-1173C8880E28Q38542034-B3C7F997-D8BC-4E04-B82F-12EAD0F75613Q39330984-EF31F8BC-DC0D-4D0C-891F-4B2BCC306952Q39698027-F2098EF3-6022-4C7C-AED4-B0994C9E6970Q42209070-EB230B7C-B2A9-4D2F-BE7A-095B49437D7AQ57911975-CB0C09E3-8CF1-4306-AB9C-F0D803673163
P2860
Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Differential internalization o ...... , cytotoxicity, and targeting.
@ast
Differential internalization o ...... , cytotoxicity, and targeting.
@en
Differential internalization o ...... , cytotoxicity, and targeting.
@nl
type
label
Differential internalization o ...... , cytotoxicity, and targeting.
@ast
Differential internalization o ...... , cytotoxicity, and targeting.
@en
Differential internalization o ...... , cytotoxicity, and targeting.
@nl
prefLabel
Differential internalization o ...... , cytotoxicity, and targeting.
@ast
Differential internalization o ...... , cytotoxicity, and targeting.
@en
Differential internalization o ...... , cytotoxicity, and targeting.
@nl
P2093
P2860
P356
P1476
Differential internalization o ...... , cytotoxicity, and targeting.
@en
P2093
Alexander L Rakhmilevich
Brett Yamane
Ilia N Buhtoiarov
Jacquelyn A Hank
Jennifer A A Gubbels
Manish S Patankar
Paul M Sondel
Ralph A Reisfeld
Stephen D Gillies
P2860
P304
P356
10.1189/JLB.0710422
P577
2011-01-19T00:00:00Z